Fig. 3

Sorafenib inhibits the CpG-A-induced production of IFNα by PBMCs or pDCs from healthy donor. A Healthy fresh PBMCs (2 × 10⁶ cells per well) seeded in 48-well plates were pretreated with the indicated concentrations of sorafenib (1 and 3 μg/mL) or DMSO (control) for 2 h prior to the stimulation with CpG-A (2.5 μM) for 6 h. BFA was added for the last 3 h of the culture. The amount of intracellular IFNα was determined by flow cytometry. The results are representative of two independent experiments. B The combined data (A) from two independent experiments involving four donors are shown. Each dot represents an individual donor, and the bars represent the mean ± S.D. *p < 0.05, **p < 0.01. C ELISA showing that sorafenib inhibits the production of IFNα by PBMCs. PBMCs (2 × 10⁵ cells per well) seeded in 96-well plates were pretreated with sorafenib at indicated doses for 2 h prior to stimulation with CpG-A for 20 h. The levels of IFNα in the culture supernatant were quantified using ELISA. Data obtained from four donors were summarized. The bars represent the mean ± S.D. *p < 0.05, **p < 0.01. D PDCs were sorted using FACS Aria III. The purified pDCs were pretreated with sorafenib for 2 h at indicated concentrations prior to stimulation with CpG-A for 20 h. The levels of IFNα in the culture supernatant were quantified using ELISA. Data from four donors were summarized. The bars represent the mean ± S.D. *p < 0.05, **p < 0.01